{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:25:44Z","timestamp":1792772744237,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"IPCA Laboratories, India"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>One-third of patients with acute severe ulcerative colitis (ASUC) fail intravenous corticosteroids. We evaluated whether adding tofacitinib to corticosteroids reduces treatment failure in ASUC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center, double-blind, placebo-controlled trial, adults with ASUC were randomized 1:1 to tofacitinib (10\u2009mg three times daily for 3\u2009days, then twice daily) or placebo for 5\u2009days alongside corticosteroids. Primary outcome was treatment failure at day 6 (&amp;lt;3-point Lichtiger reduction or total score \u226510, or colectomy). Secondary outcomes were relapse (\u22653-point rise with total \u226510), rescue therapy, and colectomy at 90\u2009days. Modified intention-to-treat analysis was performed. (CTRI\/2022\/11\/047186)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 62 randomized patients, 58 were analyzed: 33 in the tofacitinib arm and 25 in the placebo arm. The trial was terminated early because of slow recruitment and did not reach the planned sample size of 98. Day 6 treatment failure was numerically lower with tofacitinib in unadjusted analysis (24.2% vs 36.0%; RR 0.67, 95% CI 0.30-1.51; P\u2009=\u2009.33) and significantly lower after adjustment for baseline covariate imbalance (adjusted RR 0.47, 95% CI 0.24-0.93; P\u2009=\u2009.03). At 90\u2009days, colectomy rates were similar (12.1% vs 12.0%; P\u2009=\u20091.0), but more tofacitinib-treated patients remained on assigned therapy (84.4% vs 54.2%) and rescue therapy was lower (HR 0.27, 95% CI 0.09-0.78; P\u2009=\u2009.01). Serious adverse events occurred in one versus three patients. No deaths occurred with tofacitinib versus two deaths with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dual therapy with tofacitinib and steroids in ASUC did not significantly reduce treatment failure at day 6, unless adjustment for baseline imbalance in serum albumin was taken into account. It reduced the need for rescue therapy over 90 days without affecting colectomy risk. Larger clinical trials are required to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag149","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:37:45Z","timestamp":1792762665000},"source":"Crossref","is-referenced-by-count":0,"title":["Dual therapy with tofacitinib and steroids for acute severe ulcerative colitis: a randomized double-blind placebo-controlled trial"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-0776","authenticated-orcid":false,"given":"Umang","family":"Arora","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahak","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-6444","authenticated-orcid":false,"given":"Divya","family":"Madan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-4937","authenticated-orcid":false,"given":"Devasenathipathy","family":"Kandasamy","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis and Intervention Radiology, AIIMS , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Narang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjeet","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7567-8489","authenticated-orcid":false,"given":"Mridul","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K","family":"Mundhra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malambo","family":"Mubunnu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis and Intervention Radiology, AIIMS , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Panwar","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery and Liver Transplantation, AIIMS , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7481-5550","authenticated-orcid":false,"given":"Tushar","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, AIIMS , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar Ranjan","family":"Dash","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery and Liver Transplantation, AIIMS , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis and Intervention Radiology, AIIMS , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ram Manohar Lohia Hospital , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Kedia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Makharia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-8657","authenticated-orcid":false,"given":"Vineet","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS) , Delhi,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"2026102309373944700_jjag149-B1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/postgradmedj-2018-136072","article-title":"Optimal management of acute severe ulcerative colitis","volume":"95","author":"Jain","year":"2019","journal-title":"Postgrad Med J"},{"key":"2026102309373944700_jjag149-B2","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/ecco-jcc\/jjx084","article-title":"Faecal calprotectin and UCEIS predict short-term outcomes in acute severe colitis: prospective cohort study","volume":"11","author":"Jain","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026102309373944700_jjag149-B3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2022-327533","article-title":"Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response","volume":"72","author":"Adams","year":"2023","journal-title":"Gut"},{"key":"2026102309373944700_jjag149-B4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/jgh.13921","article-title":"Predictors of long-term outcomes in patients with acute severe colitis: a northern Indian cohort study","volume":"33","author":"Jain","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2026102309373944700_jjag149-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00054725-199902000-00001","article-title":"A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin","volume":"5","author":"Cohen","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"2026102309373944700_jjag149-B6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5217\/ir.2024.00112","article-title":"Short-term and long-term outcomes of acute severe ulcerative colitis in Taiwan: a multicenter study with pre- and post-biologics comparison","volume":"24","author":"Lin","year":"2026","journal-title":"Intest Res"},{"key":"2026102309373944700_jjag149-B7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/apt.16249","article-title":"Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis","volume":"53","author":"Sahu","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026102309373944700_jjag149-B8","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/ecco-jcc\/jjac190.0033","article-title":"OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)","volume":"17","author":"Raine","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026102309373944700_jjag149-B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"2026102309373944700_jjag149-B10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102309373944700_jjag149-B11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102309373944700_jjag149-B12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40273-023-01254-x","article-title":"Cost-effectiveness analysis of tofacitinib compared with biologics in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan","volume":"41","author":"Kobayashi","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"2026102309373944700_jjag149-B13","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102309373944700_jjag149-B14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis","volume":"17","author":"Berinstein","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102309373944700_jjag149-B15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"2026102309373944700_jjag149-B16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026102309373944700_jjag149-B17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12664-021-01217-0","article-title":"Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis","volume":"41","author":"Sahu","year":"2022","journal-title":"Indian J Gastroenterol"},{"key":"2026102309373944700_jjag149-B18","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"2026102309373944700_jjag149-B19","doi-asserted-by":"publisher","first-page":"otaf013","DOI":"10.1093\/crocol\/otaf013","article-title":"Tofacitinib for hospitalized acute severe ulcerative colitis management (The TRIUMPH Study)","volume":"7","author":"Narula","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"2026102309373944700_jjag149-B20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1111\/j.1572-0241.2000.02143.x","article-title":"Abnormal activation of transcription factor NF-kappaB involved in steroid resistance in chronic inflammatory bowel disease","volume":"95","author":"Bantel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2026102309373944700_jjag149-B21","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.4049\/jimmunol.169.10.5934","article-title":"A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance","volume":"169","author":"Goleva","year":"2002","journal-title":"J Immunol"},{"key":"2026102309373944700_jjag149-B22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1067\/mai.2002.122465","article-title":"p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma","volume":"109","author":"Irusen","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"2026102309373944700_jjag149-B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.20524\/aog.2022.0768","article-title":"Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series","volume":"36","author":"Komeda","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"2026102309373944700_jjag149-B24","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1007\/s10620-022-07439-2","article-title":"Effectiveness of tofacitinib for hospitalized patients with acute severe ulcerative colitis: case series","volume":"67","author":"Xiao","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2026102309373944700_jjag149-B25","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1093\/ibd\/izab181","article-title":"Success of cyclosporin and Tofacitinib combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026102309373944700_jjag149-B26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","article-title":"Sequential use of high-dose Tofacitinib after Infliximab salvage therapy in acute severe ulcerative colitis","volume":"16","author":"Gilmore","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026102309373944700_jjag149-B27","doi-asserted-by":"publisher","first-page":"jjae111","DOI":"10.1093\/ecco-jcc\/jjae111","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a systemic review and network meta-analysis","author":"Huang","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026102309373944700_jjag149-B28","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026102309373944700_jjag149-B29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026102309373944700_jjag149-B30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S2468-1253(24)00229-2","article-title":"Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better","volume":"9","author":"Kedia","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026102309373944700_jjag149-B31","doi-asserted-by":"publisher","first-page":"e001587","DOI":"10.1136\/bmjgast-2024-001587","article-title":"Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis","volume":"11","author":"Zheng","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"2026102309373944700_jjag149-B32","author":"Berinstein","year":"2025"},{"key":"2026102309373944700_jjag149-B33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/apt.70246","article-title":"Azathioprine or tofacitinib as maintenance therapy in corticosteroid-responsive acute severe ulcerative colitis","volume":"62","author":"Singh","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026102309373944700_jjag149-B34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102309373944700_jjag149-B35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","article-title":"Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis","volume":"115","author":"Kedia","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2026102309373944700_jjag149-B36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12664-023-01507-9","article-title":"Tofacitinib use in ulcerative colitis: an expert consensus for day-to-day clinical practice","volume":"43","author":"Banerjee","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"2026102309373944700_jjag149-B37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/gutjnl-2024-333281","article-title":"Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial","volume":"74","author":"Amiot","year":"2025","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag149\/72440577\/jjag149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag149\/72440577\/jjag149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:37:46Z","timestamp":1792762666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag149\/8993859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag149","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"jjag149"}}